Oxurion NV (0G99.L)
- GlobeNewswire
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – June 7, 2024 – 07:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on June 7, 2024, from Atlas Special Opportunities, LLC indicating that as of June 7, 2024, it held 1,785,024,954
- GlobeNewswire
Oxurion Announces Extraordinary General Shareholders’ Meeting
Oxurion Announces Extraordinary General Shareholders’ Meeting Leuven, BELGIUM – June 4, 2024 – 07:00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces an extraordinary general shareholders’ meeting to be held on Thursday July 4, 2024 at 11:00 AM (CET). This extraordinary general shareholders’ meeting regards the proposal of share consolidation in respect of all outstanding shares of the Company by means of a 1-for-10,000 share consolida
- GlobeNewswire
Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024
Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 Leuven, BELGIUM – 23 May, 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held its annual shareholders’ meeting on May 16, 2024. The shareholders approved all items on the agenda of the annual shareholders’ meeting. All documents pertaining to the annual shareholders' meeting held on May 16, 2024, can be consulted on Oxurion’s website Oxurion/shareholders.
